New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
09:03 EDTABT, JNJ, PCYCAbbott collaborates with Janssen and Pharmacyclics for leukemia therapy
Abbott (ABT) announced that it will collaborate with Janssen Biotech (JNJ) and Pharmacyclics (PCYC) to explore the benefits of Abbott's proprietary FISH technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia. Under the agreement, Abbott will develop a FISH-based test to identify high-risk CLL patients who have a deletion within a specific chromosome and may respond to ibrutinib, an oral, small molecule inhibitor of Bruton tyrosine kinase. Ibrutinib is currently in development by Janssen and Pharmacyclics for several B-cell malignancies, including chronic leukemia and lymphoma. Patients harboring a deletion within chromosome 17p are poor responders to chemoimmunotherapy and have limited treatment options. Having a test that is able to accurately detect the 17p deletion identifies a specific patient population with a high unmet medical need.
News For ABT;JNJ;PCYC From The Last 14 Days
Check below for free stories on ABT;JNJ;PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
15:00 EDTJNJWright Medical hip suit weakness would be buying opportunity, says Brean Capital
Subscribe for More Information
August 31, 2014
14:04 EDTJNJWorldwide Business Research to hold a conference
Subscribe for More Information
13:23 EDTABTGoldman to hold a conference
Subscribe for More Information
12:50 EDTABTEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 28, 2014
17:42 EDTJNJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
August 26, 2014
07:35 EDTPCYCPharmacyclics Imbruvica.checks positive, says Deutsche Bank
Subscribe for More Information
August 25, 2014
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 21, 2014
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 19, 2014
14:11 EDTPCYCPharmacyclics weakness on safety issues overdone, says Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use